Sex-specific differences in CYP450 isoforms in humans

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 4, 2008, Pages 413-424

  Scandlyn, Marissa J ^a   Stuart, Emma C ^a   Rosengren, Rhonda J ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

CYP2C19; CYP2C9; CYP2D6; CYP3A; Sex specific

Indexed keywords

ADINAZOLAM; ALPRAZOLAM; BROMAZEPAM; CAFFEINE; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; DEBRISOQUINE; DESIPRAMINE; DEXTROMETHORPHAN; ERYTHROMYCIN; LIDOCAINE; MIDAZOLAM; NAPROXEN; NIFEDIPINE; OMEPRAZOLE; PHENYTOIN; PIROXICAM; PROPRANOLOL; RILUZOLE; THEOPHYLLINE; TIOTIXENE; TRIAZOLAM; UNINDEXED DRUG; VERAPAMIL;

AMYOTROPHIC LATERAL SCLEROSIS; CHEMICAL REACTION; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME LOCALIZATION; EPILEPSY; HUMAN; LIVER METABOLISM; MENOPAUSE; MENSTRUATION; PHARMACOGENOMICS; PREGNANCY; REVIEW; SCHIZOPHRENIA; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HORMONES; HUMANS; ISOENZYMES; MALE; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEX FACTORS;

EID: 44349188041     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.4.413     Document Type: Review

References (139)

1. Datz F, Christian P, Moore J. Gender-related difference in gastric emptying. J Nucl Med 1987;28:1204-7
2. Hutson W, Roehrkasse R, Wald A. Influence of gender and menopause on gastric emptying and motility. Gastroenterolgy 1989;96:11-7
3. Coskun T, Sevinc A, Tevetoglu I, et al. Delayed gastric emptying in conscious male rats following chronic estrogen and progesterone treatment. Res Exp Med 1995;195:49-54
4. Wald A, Van Thiel D, Hoechstetter L, et al. Gastrointestinal transit: the effect of the menstrual cycle. Gastroenterology 1981;80:1497-500
5. Ochs H, Greenblatt D, Divoll M, et al. Diazepam kinetics in relation to age and sex. Pharmacology 1981;23:24-30
6. Magee M, Blum R, Lates C, et al. Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. J Clin Pharmacol 2001;41:1180-94
7. Kotlyar M, Carson S. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 1999;37:8-19
8. Kishino S, Nomura A, Itoh S, et al. Age- and gender-related differences in carbohydrate concentrations of alpha1-acid glycoprotein variants and the effects of glycoforms on their drug-binding capacities. Eur J Clin Pharmacol 2002;58:621-8
9. Czerniak R. Gender-based differences in pharmacokinetics in laboratory animal models. Int J Toxicol 2001;20:161-3
10. Anzenbacher P, Anzenbacherová E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 2001;58:737-47
11. Sheweita SA. Drug-metabolizing enzymes: mechanisms and functions. Curr Drug Metab 2000;1:107-32
12. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Ann Rev Pharmacol Toxicol 1999;39:1-17
13. Watkins PB, Wrighton SA, Schuetz EG, et al. Identification of glucocorticoid-inducible cytochromes P450 in the intestinal mucosa of rats and man. J Clin Invest 1987;80:1029-36
14. Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 2005;44:33-60
15. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992;44:275-83
16. Schmidt R, Baumann F, Hanschmann H, et al. Gender difference in ifosfamide metabolism by human liver microsomes. Eur J Drug Metab Pharmacokinet 2001;26:193-200
17. George J, Byth K, Farrell GC. Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. Biochem Pharmacol 1995;50:727-30
18. Schmucker DL, Woodhouse KW, Wang RK, et al. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther 1990;48:365-74
19. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23
20. Gandhi M, Aweeka F, Greenblatt RM, et al. Sex differences in pharmacokinetics and pharmacodynamics. Ann Rev Pharmacol Toxicol 2004;44:499-523
21. Fleishaker JC, Hulst LK, Ekernäs SA, et al. Pharmacokinetics and pharmacodynamics of adinazolam and N-desmethyladinazolam after oral and intravenous dosing in healthy young and elderly volunteers. J Clin Psychopharmacol 1992;12:403-14
22. Greenblatt DJ, Divoll M, Abernethy DR, et al. Alprazolam kinetics in the elderly. Relation to antipyrine disposition. Arch Gen Psychiatry 1983;40:287-90
23. Kirkwood C, Moore A, Hayes P, et al. Influence of menstrual cycle and gender on alprazolam pharmacokinetics. Clin Pharmacol Ther 1991;50:404-9
24. Kristjánsson F, Thorsteinsson SB. Disposition of alprazolam in human volunteers. Differences between genders. Acta Pharm Nord 1991; 3:249-50
25. Ochs HR, Greenblatt DJ, Friedman H, et al. Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. Clin Pharmacol Ther 1987;41:562-70
26. Austin KL, Mather LE, Philpot CR, et al. Intersubject and dose-related variability after intravenous administration of erythromycin. Br J Clin Pharmacol 1980;10:273-9
27. Watkins PB, Turgeon DK, Saenger P, et al. Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 1992;52:265-73
28. Wing LM, Miners JO, Birkett DJ, et al. Lidocaine disposition - sex differences and effects of cimetidine. Clin Pharmacol Ther 1984;35:695-701
29. Chen M, Ma L, Drusano GL, et al. Sex differences in CYP3A activity using intravenous and oral midazolam. Clin Pharmacol Ther 2006;80:531-8
30. Gorski JC, Jones DR, Haehner-Daniels BD, et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998;64:133-43
31. Greenblatt DJ, Abernethy DR, Locniskar A, et al. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984;61:27-35
32. Holazo AA, Winkler MB, Patel IH. The effect of age, gender and oral contraceptives on intramuscular midazolam pharmacokinetics. J Clin Pharmacol 1988;28:1040-5
33. Kashuba AD, Bertino JS, Rocci ML, et al. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin Pharmacol Ther 1998;64:268-77
34. Lown KS, Thummel KE, Benedict PE, et al. The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 1995;57:16-24
35. Nishiyama T, Matsukawa T, Hanaoka K. The effects of age and gender on the optimal premedication dose of intramuscular midazolam. Anesth Analg 1998;86:1103-8
36. Thummel KE, O'Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996;59:491-502
37. Tsunoda SM, Velez RL, von Moltke LL, et al. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 1999;66:461-71
38. Zhu B, Liu ZQ, Chen GL, et al. The distribution and gender difference of CYP3A activity in Chinese subjects. Br J Clin Pharmacol 2003;55:264-9
39. Greenblatt DJ, Divoll M, Abernethy DR, et al. Reduced clearance of triazolam in old age: relation to antipyrine oxidizing capacity. Br J Clin Pharmacol 1983;15:303-9
40. Greenblatt DJ, Harmatz JS, Gouthro TA, et al. Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies. Clin Pharmacol Ther 1994;56:100-11
41. Greenblatt DJ, Harmatz JS, Shapiro L, et al. Sensitivity to triazolam in the elderly. N Engl J Med 1991;324:1691-8
42. Greenblatt DJ, Harmatz JS, von Moltke LL, et al. Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin Pharmacol Ther 2004;76:467-79
43. Smith RB, Divoll M, Gillespie WR, et al. Effect of subject age and gender on the pharmacokinetics of oral triazolam and temazepam. Clin Psychopharmacol 1983;3:172-6
44. Greenblatt DJ, Harmatz JS, von Moltke LL, et al. Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. J Pharmacol Exp Ther 2000;293:435-43
45. Krecic-Shepard ME, Park K, Barnas C, et al. Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther 2000;68:130-42
46. Dadashzadeh S, Javadian B, Sadeghian S. The effect of gender on the pharmacokineties of verapamil and norverapamil in human. Biopharm Drug Dispos 2006;27:329-34
47. Kang D, Verotta D, Krecic-Shepard ME, et al. Population analyses of sustained-release verapamil in patients: effects of sex, race and smoking. Clin Pharmacol Ther 2003;73:31-40
48. Krecic-Shepard ME, Barnas CR, Slimko J, et al. Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. J Clin Pharmacol 2000;40:219-30
49. Krecic-Shepard ME, Barnas CR, Slimko J, et al. Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. Clin Pharmacol Ther 2000;68:286-92
50. Cummins CL, Wu CY, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 2002;72:474-89
51. Paine MF, Ludington SS, Chen ML, et al. Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression? Drug Metab Dispos 2005;33:426-33
52. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcin 1995;13:129-34
53. Schuetz EG, Furuya KN, Schuetz JD. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 1995;275:1011-8
54. Nishikawa A, Mori Y, Lee IS, et al. Cigarette smoking, metabolic activation and carcinogenesis. Curr Drug Metab 2004;5:363-73
55. Ou-Yang DS, Huang SL, Wang W, et al. Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. Br J Clin Pharmacol 2000;49:145-51
56. Relling MV, Lin JS, Ayers GD, et al. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992;52:643-58
57. Bock KW, Schrenk D, Forster A, et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 1994;4:209-18
58. Jennings TS, Nafziger AN, Davidson L, et al. Gender differences in hepatic induction and inhibition of theophylline pharmacokinetics and metabolism. J Lab Clin Med 1993;122:208-16
59. Ereshefsky L, Saklad SR, Watanabe MD, et al. Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. J Clin Psychopharmacol 1991;11:296-301
60. Bruno R, Vivier N, Montay G, et al. Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis. Clin Pharmacol Ther 1997;62:518-26
61. Tang YL, Mao P, Li FM, et al. Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia. Br J Clin Pharmacol 2007;64:49-56
62. Lane HY, Chang YC, Chang WH, et al. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry 1999;60:36-40
63. Nafziger AN, Bertino JS. Sex-related differences in theophylline pharmacokinetics. Eur J Clin Pharmacol 1989;37:97-100
64. May DG, Porter J, Wilkinson GR, et al. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population. Clin Pharmacol Ther 1994;55:492-500
65. Abernethy DR, Greenblatt DJ, Shader RI. Imipramine and desipramine disposition in the elderly. J Pharmacol Exp Ther 1985;232:183-8
66. McCune JS, Lindley C, Decker JL, et al. Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan. J Clin Pharmacol 2001;41:723-31
67. Aichhorn W, Weiss U, Marksteiner J, et al. Influence of age and gender on risperidone plasma concentrations. J Psychopharmacol 2005;19:395-401
68. Pritchard JF, Bryson JC, Kernodle AE, et al. Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. Clin Pharmacol Ther 1992;51:51-5
69. Gex-Fabry M, Balant-Gorgia AE, Balant LP, et al. Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data. Clin Pharmacokinet 1990:19:241-55
70. Tamminga WJ, Wemer J, Oosterhuis B, et al. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol 1999;55:177-84
71. Hägg S, Spigset O, Dahlqvist R. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers Br J Clin Pharmacol 2001;51:169-73
72. Rugstad HE, Hundal O, Holme I, et al. Piroxicam and naproxen plasma concentrations in patients with osteoarthritis: relation to age, sex, efficacy and adverse events. Clin Rheumatol 1986;5:389-98
73. Meyer MC, Straughn AB, Mhatre RM, et al. Variability in the bioavailability of phenytoin capsules in males and females. Pharm Res 2001;18:394-7
74. Travers RD, Reynolds EH, Gallagher BB. Variation in response to anticonvulsants in a group of epileptic patients. Arch Neurol 1972;27:29-33
75. Sherwin AL, Loynd JS, Bock GW, et al. Effects of age, sex obesity, and pregnancy on plasma diphenylhydantoin levels. Epilepsia 1974;15:507-21
76. Houghton GW, Richens A, Leighton M. Effect of age, height, weight and sex on serum phenytoin concentration in epileptic patients. Br J Clin Pharmacol 1975;3(2):251-6
77. Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006;58:521-90
78. Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005;77:1-16
79. Rettie AE, Tai G. The pharmocogenomics of warfarin: closing in on personalized medicine. Mol Interv 2006;6:223-7
80. Laine K, Tybring G, Bertilsson L. No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects. Clin Pharmacol Ther 2000;68:151-9
81. Xie HG, Huang SL, Xu ZH, et al. Evidence for the effect of gender on activity of (S)-mephenytoin 4′-hydroxylase (CYP2C19) in a Chinese population. Pharmacogenetics 1997;7:115-9
82. Koop DR. Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB J 1992;6:724-30
83. Tanaka E, Terada M, Misawa S. Cytochrome P450 2E1: its clinical and toxicological role. J Clin Pharm Ther 2000;25:165-75
84. Kim RB, O'Shea D. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther 1995:57:645-55
85. Chen XP, Han XM, Jiang CH, et al. Phenotype distribution and gender-related differences of CYP2E1 activity in a Chinese population. Xenobiotica 2002;32:1053-62
86. Bebia Z, Buch SC, Wilson JW, et al. Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther 2004;76:618-27
87. Sarlis N, Gougiotis L. Hormonal effects on drug metabolism through the CYP system: perspectives on their potential significance in the era of pharmacogenomics. Curr Drug Targets Immune Endocr Metabol Disord 2005;5:439-48
88. Degen L, Phillips S. Variability of gastrointestinal transit in healthy women and men. Gut 1996;39:299-305
89. Kashuba A, Nafziger A. Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet 1998;34:203-18
90. Burstein A, Reiss W, Kantor E, et al. Cytochrome P450 3A4 activity in premenopausal and postmenopausal women, based on 6-beta hydroxycortisol: cortisol ratios. Pharmacotherapy 1998;18:1271-6
91. Gorski J, Wang Z, Haehner-Daniels B, et al. The effect of hormone replacement therapy on CYP3A activity. Clin Pharmacol Ther 2000;68:412-7
92. Harris R, Tsunoda S, Mroczkowski P, et al. The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. Clin Pharmacol Ther 1996;59:429-35
93. Rubio A, Cox C. Sex, age and alfentanil pharmacokinetics. Clin Pharmacokinet 1991;21:81-2
94. Fleishaker J, Pearson L, Pearson P, et al. Hormonal effects on tirilazad clearance in women: assessment of the role of CYP3A. J Clin Pharmacol 1999;39:260-7
95. Balogh A, Klinger G, Henschel L, et al. Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination. Eur J Clin Pharmacol 1995;48:161-6
96. Palovaara S, Pelkonen O, Uusitalo J, et al. Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther 2003;74:326-33
97. Pollock B, Wylie M, Stack J, et al. Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women. J Clin Pharmacol 1999;39:936-40
98. Krecic-Shepard M, Barnas C, Slimko J, et al. In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil. Clin Pharmacol Ther 1999;66:40-50
99. Anderson G. Pregnancy-induced changes in pharmacokinetics: a mechanistics-based approach. Clin Pharmacokinet 2005;44:989-1008
100. Mattison D, Zajicek A. Gaps in the knowledge in treating pregnant women. Gend Med 2006;3:169-82
101. Dawood M. Circulating maternal serum progesterone in high-risk pregnancies. Am J Obstet Gynecol 1976;125:83240
102. Anger G, Piquette-Miller M. Pharmacokinetic studies in pregnant women. Clin Pharmacol Ther 2008;83:184-7
103. Dean M, Stock B, Patterson R, et al. Serum protein binding of drugs during and after pregnancy in humans. Clin Pharmacol Ther 1980;28:253-61
104. Dempsey D, Jacob P III, Benowitz N. Accelerated metabolism of nicotine and cotinine in pregnant smokers. J Pharmacol Exp Ther 2002;301:594-8
105. Little B. Pharmacokinetics during pregnancy: evidence-based maternal dose formulation. Obstet Gynecol 1999;93:858-68
106. McGready R, Stepniewska K, Edstein M, et al. The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. Eur J Clin Pharmacol 2003;59:545-52
107. Tsutsumi K, Kotegawa T, Matsuki S, et al. The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans. Clin Pharmacol Ther 2001;70:121-5
108. Wadelius M, Darj E, Frenne G, et al. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther 1997;62:400-7
109. Petry C, Ong K, Michelmore K, et al. Association of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women. Hum Reprod 2005;20:1837-43
110. Aklillu E, Carrillo J, Makonnen E, et al. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol 2003;64:659-69
111. Nakajima M, Yokoi T, Mizutani M, et al. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 1999;125(4):803-8
112. Sachse C, Brockmöller J, Bauer S, et al. Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47:445-9
113. Chen X, Wang W, Zhi L, et al. The G-113A polymorphism in CYP1A2 affects the caffeine metabolis ration in a Chinese population. Clin Pharmacol Ther 2005;78:249-59
114. Scordo M, Pengo V, Spina E, et al. Influence of CYP2C9 and CYP2C 19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002;72:702-10
115. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomised controlled study. Clin Pharmacol Ther 2008;3:460-70
116. Goldstein J, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997;7:59-64
117. Poolsup N, Li Wan Po A, Knight T. Pharmacogenetics and psycopharmacotherapy. J Clin Pharm Ther 2000;25:197-220
118. Sohn D, Kusaka M, Ishizaki T, et al. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992;52:160-9
119. Basci N, Brosen K, Bozkurt A, et al. S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population. Br J Clin Pharmacol 1994;38:463-5
120. Bertilsson L, Lou Y, Du Y, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-97
121. Desta Z, Zhao X, Shin J-G, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002;41:913-58
122. Jacqz E, Dulac H, Mathieu H. Phenotyping polymorphic drug metabolism in the French Caucasian population. Eur J Clin Pharmacol 1988;35:167-71
123. Skjelbo E, Mutabingwa T, Bygbjerg I, et al. Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Clin Pharmacol Ther 1996;59:304-11
124. de Morais S, Goldstein J, Xie H, et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995;58:404-11
125. de Morais S, Wilkinson G, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8
126. de Morais S, Wilkinson G, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22
127. Ferguson R, De Morais S, Benhamou S, et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998;284:356-61
128. Ibeanu G, Blaisdell J, Ferguson R, et al. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther 1999;290:635-40
129. Ibeanu G, Blaisdell J, Ghanayem B, et al. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 1998;8:129-35
130. Ibeanu G, Goldstein J, Meyer U, et al. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther 1998;286:1490-5
131. Romkes M, Faletto M, Blaisdell J, et al. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 1991;30:3247-55
132. Xiao Z, Goldstein J, Xie H, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 1997;281:604-9
133. Chiba K, Kobayashi K, Manabe K, et al. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther 1993;266:52-9
134. Skjelbo E, Brøsen K, Hallas J, et al. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 1991;49:18-23
135. Skjelbo E, Grato L, K B. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio): a population study. Br J Clin Pharmacol 1993;35:331-4
136. Wilkinson G, Guengerich F, Branch R. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989;43:53-76
137. Yasumori T, Nagata K, Yang S, et al. Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. Pharmacogenetics 1993;3:291-301
138. Cascorbi I. Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication. Eur J Clin Invest 2003;33:17-22
139. Zanger U, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369:23-37